Lanreotide
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Lanreotide: From Acromegaly/Neuroendocrine Tumors to Hypertrichosis
One-Sentence Summary
Lanreotide is a somatostatin analog originally used for acromegaly and neuroendocrine tumors, working by suppressing growth hormone/IGF-1 secretion and cell proliferation. The TxGNN model predicts it may be effective for Hypertrichosis, but this is currently a pure computational prediction with zero supporting clinical trials or literature, and the model’s own mechanistic analysis found no known pharmacological link between the drug and this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acromegaly, neuroendocrine tumors (per drug’s known somatostatin-analog mechanism; not separately confirmed by a formal indication record in this evidence pack) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 (model prediction only — no clinical trials or literature found) |
| Market Status (this jurisdiction) | ✗ Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the evidence pack (flagged as a High-severity data gap). Based on known drug class information, lanreotide is a somatostatin analog whose established pharmacology is inhibition of growth hormone/IGF-1 secretion and antiproliferative effects, underlying its use in acromegaly and neuroendocrine tumors.
For the top-ranked prediction, hypertrichosis, the model’s own mechanistic assessment is explicitly negative: it states there is no known receptor or pathway connection between somatostatin signaling and hair follicle biology, and that the high TxGNN score (0.9997) reflects knowledge-graph structural similarity rather than any pharmacological rationale. In other words, the evidence pack itself concludes this prediction lacks mechanistic support.
The four lower-ranked candidates (odontal/periodontal malformation syndrome, Dandy-Walker malformation syndrome, isolated genetic hair shaft abnormality, Ambras-type congenital hypertrichosis) show the same pattern — high TxGNN scores with no identified mechanistic or clinical connection to somatostatin pharmacology. The 20 literature hits attached to the periodontal-component candidate are general periodontology papers that do not mention lanreotide or somatostatin pathways, and are best interpreted as keyword-matching noise rather than drug-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The drug is not marketed in this jurisdiction (0 licenses on file), so no marketing authorization records are available.
Safety Considerations
Please refer to the package insert for safety information. (TFDA label warnings/contraindications and drug-interaction data are currently unavailable — this is flagged as a Blocking data gap that must be resolved before any safety evaluation can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate rests entirely on a TxGNN structural-similarity score (L5), with zero clinical trials, zero supporting literature, and the model’s own rationale explicitly stating no known mechanistic link to hypertrichosis. Combined with the absence of any safety/label data for this drug (a blocking gap), there is no basis to advance this candidate at this time.
To proceed, the following is needed:
- TFDA label warnings and contraindications (currently blocking — required before any safety pre-screening)
- Confirmed mechanism-of-action data from DrugBank or primary literature
- Independent pharmacological or preclinical rationale connecting somatostatin signaling to hair growth/follicle biology, if this candidate is to be pursued further
- Re-query of clinical trial registries and literature databases periodically, as current searches returned no hits
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.